| Schedule of segment and geographic area information |
|
|
|
Net Sales to External Customers |
|
Operating Earnings |
|
|
|
|
Three Months |
|
Six Months |
|
Three Months |
|
Six Months |
|
|
|
|
Ended June 30 |
|
Ended June 30 |
|
Ended June 30 |
|
Ended June 30 |
|
|
(in millions) |
|
2014 |
|
2013 |
|
2014 |
|
2013 |
|
2014 |
|
2013 |
|
2014 |
|
2013 |
|
|
Established Pharmaceutical Products |
|
$ |
1,216 |
|
$ |
1,218 |
|
$ |
2,367 |
|
$ |
2,450 |
|
$ |
245 |
|
$ |
258 |
|
$ |
475 |
|
$ |
543 |
|
|
Nutritional Products |
|
1,731 |
|
1,704 |
|
3,362 |
|
3,404 |
|
302 |
|
313 |
|
585 |
|
655 |
|
|
Diagnostic Products |
|
1,189 |
|
1,135 |
|
2,306 |
|
2,223 |
|
279 |
|
242 |
|
501 |
|
503 |
|
|
Vascular Products |
|
765 |
|
751 |
|
1,503 |
|
1,492 |
|
303 |
|
221 |
|
524 |
|
408 |
|
|
Total Reportable Segments |
|
4,901 |
|
4,808 |
|
9,538 |
|
9,569 |
|
1,129 |
|
1,034 |
|
2,085 |
|
2,109 |
|
|
Other |
|
650 |
|
638 |
|
1,257 |
|
1,255 |
|
|
|
|
|
|
|
|
|
|
Net Sales |
|
$ |
5,551 |
|
$ |
5,446 |
|
$ |
10,795 |
|
$ |
10,824 |
|
|
|
|
|
|
|
|
|
|
Corporate functions and benefit plans costs |
|
|
|
|
|
|
|
|
|
(103 |
) |
(127 |
) |
(161 |
) |
(247 |
) |
|
Non-reportable segments |
|
|
|
|
|
|
|
|
|
105 |
|
99 |
|
168 |
|
187 |
|
|
Net interest expense |
|
|
|
|
|
|
|
|
|
(20 |
) |
(23 |
) |
(43 |
) |
(49 |
) |
|
Share-based compensation (a) |
|
|
|
|
|
|
|
|
|
(49 |
) |
(52 |
) |
(168 |
) |
(177 |
) |
|
Amortization of intangible assets |
|
|
|
|
|
|
|
|
|
(161 |
) |
(197 |
) |
(335 |
) |
(396 |
) |
|
Other, net (b) |
|
|
|
|
|
|
|
|
|
(164 |
) |
(133 |
) |
(386 |
) |
(272 |
) |
|
Consolidated Earnings from Continuing Operations Before Taxes |
|
|
|
|
|
|
|
|
|
$ |
737 |
|
$ |
601 |
|
$ |
1,160 |
|
$ |
1,155 |
|
(a) Approximately 40 to 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b) The increase in expense from 2013 to 2014 primarily reflects higher charges for cost reduction initiatives. |